ArticleScientific reports2026
Stabilization of Niaouli essential oil-loaded gelatin nanofibers: characterization and in vitro evaluation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Niaouli essential oil (NEO), obtained from Melaleuca quinquenervia leaves, is a plant-derived active compound with high biological activity properties; however, its direct use is limited due to its hydrophobicity, volatility, and instability. In this study, biologically active and mechanically enhanced nanofiber-based drug delivery systems were developed by directly incorporating NEO into gelatin (G)-based electrospun nanofibers and enhancing their stability through chemical crosslinking with glutaraldehyde (GTA) vapor. In this context, electrospun nanofibers loaded with NEO concentrations of 1% (GN1), 5% (GN5), and 10% v/v (GN10). They were exposed to the vapor generated by the GTA solution for different durations (10, 30 min, 1 h, and 3 h), temperature settings (25 and 50 °C), and two different volumes (50 and 100 µL). Morphological analysis and water solubility tests were performed to determine the optimal crosslinking conditions. Subsequently, both GN1 and GN5 NEO-loaded nanofibers, crosslinked for 1 h and 3 h were comprehensively characterized in terms of morphology, chemical structure, wettability, mechanical strength, thermal stability, in vitro drug release behavior, and antimicrobial activity. Following 3 h of crosslinking, GN1_C3 nanofibers exhibited a rapid initial release (92% in ~ 120 h), while GN5_C3 nanofibers provided a slower, sustained release (75% in ~ 240 h). Biological evaluations using MTT assay, fluorescence microscopy, and SEM confirmed high cytocompatibility and effective support of L929 fibroblast adhesion and proliferation. Strong antibacterial activity was observed against S. aureus and E. coli for GN5_C3. To the best of our knowledge, this is the first study reporting the direct incorporation of NEO into electrospun nanofibers. The fabricated NEO-loaded and crosslinked nanofibers represent a platform for tissue engineering and antimicrobial applications due to their high biological and antimicrobial properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.